Biohaven Ltd. (NYSE:BHVN) Stock Holdings Raised by ARS Investment Partners LLC

ARS Investment Partners LLC boosted its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 1.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,040,712 shares of the company's stock after buying an additional 10,473 shares during the quarter. Biohaven makes up 3.5% of ARS Investment Partners LLC's investment portfolio, making the stock its 6th largest holding. ARS Investment Partners LLC owned 1.03% of Biohaven worth $38,871,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hsbc Holdings PLC grew its holdings in shares of Biohaven by 6.1% in the second quarter. Hsbc Holdings PLC now owns 8,291 shares of the company's stock valued at $286,000 after acquiring an additional 480 shares in the last quarter. Inspire Investing LLC boosted its position in Biohaven by 57.5% in the second quarter. Inspire Investing LLC now owns 10,150 shares of the company's stock worth $352,000 after purchasing an additional 3,706 shares during the last quarter. Public Employees Retirement Association of Colorado grew its stake in Biohaven by 114.5% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 7,796 shares of the company's stock valued at $271,000 after purchasing an additional 4,162 shares during the period. Profund Advisors LLC increased its position in shares of Biohaven by 42.4% during the 2nd quarter. Profund Advisors LLC now owns 36,239 shares of the company's stock valued at $1,258,000 after purchasing an additional 10,786 shares during the last quarter. Finally, Hood River Capital Management LLC raised its stake in shares of Biohaven by 9.6% during the 2nd quarter. Hood River Capital Management LLC now owns 368,902 shares of the company's stock worth $12,805,000 after purchasing an additional 32,448 shares during the period. 88.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BHVN has been the subject of several research reports. Piper Sandler increased their price target on shares of Biohaven from $66.00 to $76.00 and gave the company an "overweight" rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. raised their price target on shares of Biohaven from $55.00 to $68.00 and gave the stock an "overweight" rating in a research note on Thursday, October 3rd. TD Cowen upped their price objective on Biohaven from $55.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reissued an "overweight" rating on shares of Biohaven in a research report on Tuesday, December 17th. Finally, HC Wainwright restated a "buy" rating and issued a $59.00 target price on shares of Biohaven in a research note on Tuesday, December 17th. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Biohaven presently has a consensus rating of "Buy" and a consensus target price of $63.00.

Insider Buying and Selling

In other news, Director John W. Childs bought 29,000 shares of the business's stock in a transaction on Monday, December 30th. The stock was acquired at an average price of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the purchase, the director now directly owns 2,368,741 shares in the company, valued at $85,132,551.54. This represents a 1.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 16.00% of the stock is currently owned by company insiders.

Biohaven Price Performance

Shares of BHVN traded up $1.50 during midday trading on Tuesday, hitting $39.09. 763,975 shares of the company traded hands, compared to its average volume of 1,100,139. The stock has a 50-day moving average of $40.80 and a 200-day moving average of $42.43. Biohaven Ltd. has a one year low of $26.80 and a one year high of $62.21. The firm has a market cap of $3.95 billion, a P/E ratio of -4.18 and a beta of 1.29.

Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.03). Sell-side analysts forecast that Biohaven Ltd. will post -8.85 EPS for the current fiscal year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.